---
$id: https://graph.org.ai/products/commodity/51112003
$type: Product
source: UNSPSC
code: "51112003"
title: "Erlotinib"
class: "51112000"
classTitle: "Tyrosine kinase inhibitors"
family: "51110000"
familyTitle: "Antineoplastic agents"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Erlotinib

**UNSPSC Code**: 51112003
**Class**: [Tyrosine kinase inhibitors](Tyrosine kinase inhibitors.mdx)
**Family**: [Antineoplastic agents](../Antineoplastic agents.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes an epidermal growth factor receptor tyrosine kinase inhibitor with the molecular formula C22H23N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J4T82NDH7E, chemically known as 4-quinazolinamine, n-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, but generally known as erlotinib, which bears US NIH Compound Identifier 176870. European Medicines Agency schedules Erlotinib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16423MIG. The term ERLOTINIB is an International Non-Proprietary Name. World Health Organization schedules erlotinib in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule erlotinib under HS 29335995 and SITC 51576. As of Q4 2014, ERLOTINIB remains the US FDA Preferred Term for this commodity. Erlotinib bears US NLM identifiers UMLS ID C1135135 and NCI Concept Code C65530. SMILES: O(C1C(OCCOC)CC2NCNC(NC3CC(CCC3)C#C)C2C1)CCOC.

